Please login to the form below

Not currently logged in
Email:
Password:

Zolgensma

This page shows the latest Zolgensma news and features for those working in and with pharma, biotech and healthcare.

EU authorises Roche’s spinal muscular atrophy treatment Evrysdi

EU authorises Roche’s spinal muscular atrophy treatment Evrysdi

Evrysdi becomes the third drug approved to treat the condition, following Biogen's Spinraza (nusinersen) and Novartis' Zolgensma (onasemnogene abeparvovec), and is the first that can be administered orally.

Latest news

More from news
Approximately 20 fully matching, plus 36 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
KVA Digital

KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....